Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, +6

International Journal of Cancer

Mortality WorldwideCancer ManagementEpidemiology Of CancerPathologyCancer Incidence +15

Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex

Dos D. Sarbassov, David A. Guertin, Siraj M. Ali, +1

Science

Molecular BiologyTumor BiologySignaling PathwayAkt/pkb ActivationReceptor Tyrosine Kinase +14

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Makoto Maemondo, Akira Inoue, Kunihiko Kobayashi, +20

New England Journal of Medicine

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais, +54

The Lancet Oncology

OncologyStandard ChemotherapyRandomised Phase 3PathologyBronchial Neoplasm +6

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Tetsuya Mitsudomi, Satoshi Morita, Yasushi Yatabe, +18

The Lancet Oncology

Open LabelMedicineCancer GrowthPathologyCancer Genomics +8

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou, Yi‐Long Wu, Gongyan Chen, +21

The Lancet Oncology

MedicinePathologyBronchial NeoplasmFirst-line TreatmentCancer Treatment +6

<i>EGFR</i> Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Susumu Kobayashi, Titus J. Boggon, Tajhal Dayaram, +7

New England Journal of Medicine

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

William Pao, Vincent A. Miller, Katerina Politi, +5

PLoS Medicine

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Lecia V. Sequist, James Chih‐Hsin Yang, Nobuyuki Yamamoto, +15

Journal of Clinical Oncology

Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα

Dario R. Alessi, Stephen R. James, C. Peter Downes, +4

Current Biology

Signal TransductionMolecular PhysiologySignaling PathwayNatural SciencesMolecular Biology +9